Gene mutations, copy-number variations, and rearrangements in the receptor tyrosine kinase-MAPK and PI3K-MTOR pathways are detected in ~ 70% of BC patients, which fosters the development of new therapies against these targets [16]. The gene discussed is MTOR; the disease is breast cancer.